Telomir Pharmaceuticals (NASDAQ: TELO) has raised approximately $5.6 million through a private investment in public equity (PIPE) financing, issuing 4,843,300 common shares at $1.16 per share. The pricing reflects a 5% discount to the applicable 10-day volume-weighted average price. The financing includes an additional $1 million investment from existing significant shareholder John Paul DeJoria and notably does not include investor warrants, convertible securities, or variable-price or reset features.
The net proceeds are primarily earmarked to support clinical development of Telomir-Zn, the company’s lead small-molecule therapeutic, including its Phase 1/2 clinical program in advanced or metastatic triple-negative breast cancer (TNBC), as well as for working capital and general corporate purposes. The FDA has cleared the company’s Investigational New Drug (IND) application for Telomir-Zn, enabling it to proceed with its first-in-human Phase 1/2 trial in patients with advanced or metastatic TNBC. For full details, see the complete press release.
Triple-negative breast cancer is an aggressive subtype that lacks estrogen, progesterone, and HER2 receptors, limiting treatment options and often leading to poor outcomes. The launch of a first-in-human trial for Telomir-Zn represents a critical step toward addressing this unmet medical need. Telomir-Zn is designed to modulate intracellular metal homeostasis and epigenetic regulation, targeting epigenetic and metabolic pathways implicated in cancer. If successful, this approach could offer a novel mechanism of action for patients who currently have few effective therapies.
The financing structure, without warrants or reset provisions, may be viewed favorably by investors as it avoids potential dilution overhangs and signals confidence from existing backers like DeJoria. The participation of a significant shareholder further underscores belief in the company’s direction. For the broader biotechnology industry, this deal highlights continued investor appetite for well-structured financings that fund late-preclinical to early-clinical assets, particularly in oncology. It also reinforces the importance of IND clearance as a value-inflection point for small-cap biotechs.
Telomir Pharmaceuticals is a clinical-stage biotechnology company developing small-molecule therapeutics targeting epigenetic and metabolic pathways implicated in cancer. The company’s lead program, Telomir-Zn, is designed to modulate intracellular metal homeostasis and epigenetic regulation and has received IND clearance from the U.S. Food and Drug Administration for a Phase 1/2 clinical trial in patients with advanced or metastatic TNBC. The latest news and updates relating to TELO are available in the company’s newsroom.
The announcement was disseminated through InvestorWire, a specialized communications platform focused on advanced wire-grade press release syndication. InvestorWire is one of 75+ brands within the Dynamic Brand Portfolio at IBN, offering services such as editorial syndication to 5,000+ outlets, press release enhancement, and social media distribution.
